Nanomedicines for Breast Cancer Theranostics

0532010 - ÚŽFG 2021 RIV NL eng M - Monography Chapter
Rohiwal, Sonali Suresh - Tiwari, A. P.
Consensus protocols for animal experimentation and nanomedicine trials at clinical stage in breast cancer.
Nanomedicines for Breast Cancer Theranostics. Amsterdam: Elsevier, 2020 - (Thorat, N.; Bauer, J.), s. 331-349. Micro & Nano Technologies. ISBN 978-0-12-820017-9
Institutional support: RVO:67985904
Keywords : animal models * anti-Cancer drugs * Breast cancer
OECD category: Oncology

The use of nanotechnology in medicine has a potential impact on human health in terms of its prevention, diagnosis, and treatment of life-threatening diseases, such as cancer. Nanomedicine provides detection of cancer and enhances its treatment efficiency by minimizing the diverse effect associated with the standard therapies. It deals with delivering of various drugs via various mechanisms such as active and passive targeting and triggered release of encapsulated content by solubilization and reduces the risk of systemic side effects. Several experimental challenges need to be conquered to address from bench to besides. Herein, we discussed the clinical translations of nanomedicines its development and commercialization in terms of various drugs. Furthermore, the issues related to development of materials is explored in detail including large-scale manufacturing, biological challenges, biocompatibility and safety, government regulations, and several animal nonpredictive animal models in comparison to current therapies.
Permanent Link: http://hdl.handle.net/11104/0310614